Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Dec

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer

Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers

T-DXd Plus Pertuzumab in HER2-Positive Advanced or Metastatic Breast Cancer

AACR Pediatric Cancer Progress Report 2025

Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma